Company: BSX
Filing Date: 2025-04-23
Form Type: 8-K
Source: 0000885725-25-000024
Chunk: 0

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-04-23
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;

Compensatory Arrangements of Certain Officers.

On April 23, 2025, Boston Scientific Corporation (the “ Company”) announced that Daniel J. Brennan has decided to retire from his role as Executive Vice President and Chief Financial Officer of the Company effective as of June 29, 2025, and that Jonathan Monson, who currently serves as Senior Vice President, Investor Relations, has been promoted to Executive Vice President and Chief Financial Officer of the Company effective as of June 30, 2025.

Mr. Brennan is expected to remain with the Company as a senior advisor from such time through October 3, 2025 (such date, or any earlier date, the “ Retirement Date”). As a senior advisor, Mr. Brennan will receive a base salary at his current annual base salary of $880,000, prorated through the Retirement Date.

The Company expects to enter into a Retirement Agreement with Mr. Brennan effective as of the Retirement Date, pursuant to which Mr. Brennan will be entitled to payments and benefits that are materially consistent with those Mr. Brennan is entitled to under, and subject to the terms and conditions of, the Company’s Executive Retirement Plan, 2025 Annual Bonus Plan (the “2025 ABP”) and 2023 and 2024 Organic Net Sales Growth Performance Share Programs and 2023 and 2024 Relative Total Shareholder Return Performance Share Programs, respectively, each as previously filed with the U. S. Securities and Exchange Commission (the “ SEC”).

Mr. Monson, age 51, joined the Company in 1999, and has served in a number of roles of increasing responsibility. Mr. Monson currently serves as the Company’s Senior Vice President, Investor Relations, a position he has held since March 2024. In this role, he leads the Company’s Investor Relations function, including engagement with investors and analysts. Prior to that, Mr. Monson served as Global Controller and Chief Accounting Officer from July 2019 to March 2024, where he was responsible for the Company’s Global Controllership organization, including, among other things, the Company’s accounting and financial planning processes. Prior to that, Mr. Monson served in various roles within finance and accounting, including as Vice President and Controller of the Company’s Urology business from 2016 to 2019, and Vice President, Corporate Accounting from 2008 to